Pure Global
NCT06411548

Insulearn Feasibility With MDI

Feasibility of a Bolus Calculator Without Carbohydrate Counting in T1D Patients Under MDI Therapy: A Supervised Randomized Controlled Trial
University of Virginia·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 1 Diabetes Mellitus
Drug/Device/Intervention
InsuLearn
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
University of Virginia
Location
Charlottesville, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Dec 31, 2024
Enrollment
10 participants
Primary outcome

Low blood glucose index (LBGI)

Summary

This is a 24-hour, randomized, crossover, single-center trial where participants are
 randomized to either start with the InsuLearn intervention or the usual care (UC)
 intervention. In the InsuLearn intervention, insulin doses are optimized using data collected
 in a 4-weeks at home data collection period.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06411548
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06411548 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Virginia and is currently Not yet recruiting. The study focuses on Type 1 Diabetes Mellitus. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.